Document And Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Mar. 31, 2025 |
Jun. 30, 2024 |
|
| Document Information Line Items | |||
| Entity Central Index Key | 0001690080 | ||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Transition Report | false | ||
| Entity File Number | 001-38105 | ||
| Entity Registrant Name | 180 LIFE SCIENCES CORP. | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 90-1890354 | ||
| Entity Address, Address Line One | 3000 El Camino Real, Bldg. 4 | ||
| Entity Address, Address Line Two | Suite 200 | ||
| Entity Address, City or Town | Palo Alto | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94306 | ||
| City Area Code | (650) | ||
| Local Phone Number | 507-0669 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 1,548,662 | ||
| Entity Common Stock, Shares Outstanding | 5,185,780 | ||
| Documents Incorporated by Reference [Text Block] | None | ||
| Amendment Description | On March 31, 2025, 180 Life Sciences Corp. (“180 Life,” the “Company,” “we,” “us,” or “our”) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Form 10-K”) with the U.S. Securities and Exchange Commission (the “SEC”). The Original Form 10-K omitted certain disclosures under Part III, Items 10, 11, 12, 13 and 14 of Form 10-K in reliance on General Instruction G(3) to Form 10-K, which provides that such information may be either incorporated by reference from the registrant’s definitive proxy statement or included in an amendment to Form 10-K, in either case filed with the SEC not later than 120 days after the end of the fiscal year.We currently do not expect to file our definitive proxy statement for the 2025 annual meeting of our stockholders within 120 days of December 31, 2024. Accordingly, we are filing this Amendment No. 1 to the Original Form 10-K (this “Amendment No. 1”) solely to: ● amend Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters), 13 (Certain Relationships and Related Transactions, and Director Independence) and 14 (Principal Accountant Fees and Services) of the Original Form 10-K to include the information required to be disclosed under such Items; ● delete the reference on the cover of the Original Form 10-K regarding the incorporation by reference into Part III of the Original Form 10-K of portions of our definitive proxy statement to be delivered to stockholders and filed with the SEC in connection with the 2025 annual meeting of our stockholders; and ● file new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment under Item 15 of Part IV hereof, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Amendment No. 1 does not otherwise change or update any of the disclosures set forth in the Original Form 10-K, and, except as expressly stated herein, does not reflect events occurring after the filing of the Original Form 10-K. This Amendment No. 1 modifies and amends the Original Form 10-K, and should be read in conjunction with the Original Form 10-K. References to “this Annual Report” contained in this Amendment No. 1 refer to the Original Form 10-K, as modified and amended by this Amendment No. 1. Capitalized terms not otherwise defined in this Amendment No. 1 have the meanings given to them in the Original Form 10-K.Unless the context requires otherwise, references to the “Company,” “we,” “us,” “our,” “180 Life”, “180LS” and “180 Life Sciences Corp.” refer specifically to 180 Life Sciences Corp. and its consolidated subsidiaries. References to “KBL” refer to the Company prior to our November 6, 2020 Business Combination.In addition, unless the context otherwise requires and for the purposes of this Report only: ● “180” refers to 180 Life Corp. (f/k/a 180 Life Sciences Corp.), our wholly-owned subsidiary. “Business Combination” means that certain business combination which closed on November 6, 2020, between KBL, KBL Merger Sub, Inc. (“Merger Sub”), 180, Katexco Pharmaceuticals Corp. (“Katexco”), CannBioRex Pharmaceuticals Corp. (“CBR Pharma”), 180 Therapeutics L.P. (“180 LP” and together with Katexco and CBR Pharma, the “180 Subsidiaries” and, together with 180 Life Sciences Corp., the “180 Parties”), and Lawrence Pemble, in his capacity as representative of the stockholders of the 180 Parties, whereby KBL acquired the 180 Subsidiaries. ● “CAD” refers to Canadian dollars; ● “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; ● “£” or “GBP” refers to British pounds sterling; ● “SEC” or the “Commission” refers to the United States Securities and Exchange Commission; and ● “Securities Act” refers to the Securities Act of 1933, as amended. | ||
| Amendment Flag | true | ||
| Document Fiscal Period Focus | FY | ||
| Common Stock, par value $0.0001 per share | |||
| Document Information Line Items | |||
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
| Trading Symbol | ATNF | ||
| Security Exchange Name | NASDAQ | ||
| Warrants to purchase shares of Common Stock | |||
| Document Information Line Items | |||
| Title of 12(b) Security | Warrants to purchase shares of Common Stock | ||
| Trading Symbol | ATNFW | ||
| Security Exchange Name | NASDAQ |